We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Galapagos Achieves Milestone Payment in Rheumatoid Arthritis Alliance

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Galapagos Achieves Milestone Payment in Rheumatoid Arthritis Alliance"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
Galapagos NV announced has achievement of a milestone under its alliance agreement in rheumatoid arthritis with Janssen Pharmaceutica NV. The milestone triggered a cash payment of €3.4 million to Galapagos.

In October 2007, Galapagos announced an alliance agreement with Janssen providing Janssen with option rights to acquire worldwide, commercial licenses to novel small molecules from up to 12 of Galapagos' internal programs involving rheumatoid arthritis therapeutic targets. The milestone is the result of one of these programs reaching the next phase of medicinal chemistry optimization.